WHAT IS DSIP

Delta Sleep Inducing Peptide (DSIP) is a naturally occurring nonapeptide, originally discovered back in 1974 by researchers who infused venous blood from the cerebral sagittal sinus of sleeping rabbits into awake rabbits. It was named thanks to its observed effect of inducing delta-wave activity during measurement with an EEG. This corresponds to deep slow-wave sleep.

WHAT DOES DSIP DO?

While in the body, it has shown the ability to regulate sleep cycles, modulate stress hormones like cortisol, and even influence pituitary hormone release (Such as LH or GH). While it occurs naturally in small amounts, the version that is utilized in research and supplementation is a synthetic form designed to mimic the body's own natural peptide. 

• Sleep Architecture Modulation: As its namesake suggests, it induces SWS sleep and Delta Sleep.

• Stress and HPA Axis Regulation: Research suggests it may function as an adaptogen, helping the body cope with psychological and physical stress. 

• Endocrine and Hormone Release: It has been implicated in regulating the nocturnal surge of certain hormones, such as stimulating the secretion of somatoliberin (GHRH) and somatotropin (Growth Hormone). It also influences melatonin production and may reduce basal corticotropin levels.

• Neuroprotection and Anticonvulsant Properties: Studies suggest DSIP stabilizes neural activity, reduces excitotoxicity, and possesses anti-convulsant properties, potentially by potentiating the action of anti-epileptic drugs in seizure models.

• Pain Modulation: DSIP is hypothesized to have analgesic-like properties, possibly by influencing opioid receptor activity and modulating pain signal transmission pathways.

Although DSIP is not fully understood, its discovery suggested that sleep quality could be influenced at the peptide level, opening the door to new approaches for recovery and performance.

BENEFITS/ CLINICAL TRIALS

DSIP has been researched extensively. Most studies consist of small human pilot studies conducted in the 1980s and a large body of animal preclinical data arising after the fact.  

Clinical Trial Findings:

Early human trials on insomnia have shown that intravenous administration of DSIP significantly improved sleep parameters and had greater sleep efficiency alongside SWS time in chronic insomniacs. With repeated administrations leading to a buildup effect. This normalized the structure of sleep after several consecutive doses. 

SIDE EFFECTS

DSIP is generally well-tolerated in research protocols due to its function as a natural neuro-modulator rather than a systemic sedative.

•  Effects include:

  • Lethargy/Fatigue: If the dosage is too high or administered at an inappropriate time, it may cause excessive fatigue or lethargy upon waking.

  • Headache/Dizziness: Occasionally reported, particularly with rapid injection/infusion.

  • Mood: In rare cases, double daily doses were reported to negatively affect activity levels.

• Local Reactions:

  • Injection Site Reactions: Mild irritation, redness, or swelling at the subcutaneous injection site.

IS DSIP SAFE?

DSIP is a naturally occurring nonapeptide, and its demonstrated properties in controlled preclinical and small human studies suggest a low risk of toxicity.

DSIP is not approved by the FDA or any major global regulatory body for human therapeutic use. Its safety has not been confirmed through large, long-term Phase 3 clinical trials. While it appears to have a gentler profile than traditional hypnotics, the long-term effects of exogenous administration, its exact metabolic fate, and potential for interaction with complex neuroendocrine disorders remain unknown outside of controlled research settings.

DOSAGE

Standard clinical dosing for DSIP has not been established. Protocols are based on early research in small cohorts.

• Administration: Typically administered via subcutaneous or slow intravenous injection. Intranasal administration has also been investigated in some preclinical models.

• Dosage Range (Based on Research):

  • Microgram Range: Common initial research doses range from 100 mcg to 300 mcg daily.

  • Nmol/kg Range (Historical): Some early studies used 25 nmol/kg body weight, translating to approximately 2 mg for an 80 kg subject much higher dose than currently reported in wellness protocols.

• Timing: Dosing is most often administered in the evening, shortly before bedtime, to align with its hypothesized promotion of SWS and natural circadian rhythms.

• Cycle Length: Research protocols vary, but use is generally suggested for 3-5 days weekly or continuously for 4-8 weeks to achieve normalization of sleep architecture.

RECONSTITUTION

DSIP is supplied as a lyophilized (freeze-dried) powder and requires reconstitution with sterile water.

• Reconstitution Fluid: Use sterile or bacteriostatic water BAC Water.

• Standard Dilution 5mg Vial): For a 5mg vial, adding 2 mL of BAC Water yields a concentration of 2.5 mg/mL (2,500 mcg/mL).

  • Note: This high concentration minimizes injection volume for the microgram dosing range.

• Mixing Technique: Inject the BAC Water slowly down the side of the vial. DO NOT SHAKE vigorously. Gently swirl or roll the vial between your hands for several minutes until the powder is completely dissolved and the solution is clear.

• Post-Reconstitution Storage: Once reconstituted, the solution must be stored in the refrigerator 2C to 8C or 34F to 36F and is typically stable for 14 to 28 days.

WHERE TO BUY DSIP

Researchers should always vet their sources to ensure that a few key factors are present in their test subjects. With the rise in peptide popularity in recent years, many companies have created peptides that undergo little to no testing, quality standards, or regulations. As it is not regulated by the FDA, researchers must do their due diligence and look closely at the company's practices and standards. 

When selecting a supplier for DSIP, focus on transparency and quality assurance, not customer testimonials:

1. Quality Documentation: A reputable supplier must provide:
   •  Certificate of Analysis (COA): This document must be recent (corresponding to the batch/lot number purchased) and demonstrate a minimum purity of >95% via High-Performance Liquid Chromatography (HPLC) testing.
   • Mass Spectrometry (MS) Data: The COA must include mass spectrometry (MS) confirmation to verify the compound’s exact molecular weight, confirming its chemical identity.
   • Contaminant Testing: Look for reports on heavy metals, microbial load, and solvent residues (e.g., residual trifluoroacetic acid, or TFA). The presence of these contaminants can severely compromise research and introduce unknown toxicity.
2. Vendor Verification and Transparency 

   • Specialization: Prioritize vendors who specialize in the manufacturing and distribution of peptides for academic and biotechnology research, rather than general supplement vendors.

   • Manufacturing Origin: Inquire about the source of the raw materials and the manufacturing protocols. Ideal suppliers adhere to strict quality control processes.

   • Handling & Storage: The supplier must provide clear documentation on the proper storage and handling procedures for the peptide to maintain its stability and integrity.

Conclusion on Procurement: Given the high risk of contamination, mislabeling, and legal ambiguity. The use of DSIP outside of this defined research context poses unacceptable, unquantified risks to human health.

REFERENCES

• Innerbody. "DSIP (Delta Sleep-Inducing Peptide) $\text{Full}$ Rundown."
• Phoenix Pharmaceuticals, Inc. "DSIP (Delta Sleep-Inducing Peptide)."
• PubMed (ID 6391925). "DSIP in Insomnia."
• MDPI (ID 1420-3049/26/17/5173). "Delta Sleep-Inducing Peptide Recovers Motor Function in $\text{SD}$ Rats after Focal Stroke."
• Revolution Health. "DSIP Peptide: The Sleep-Optimizing Molecule for Deep Rest and Recovery."
• ChemicalBook. "Is $\text{DSIP}$ Delta-Sleep-Inducing Peptide Safety?"
• by, Written. “DSIP (Delta Sleep-Inducing Peptide): Benefits, Dosage, and Risks Expla.” Swolverine, swolverine.com/blogs/blog/dsip-delta-sleep-inducing-peptide-benefits-dosage-and-risks-explained?_pos=1&_sid=ba6a70709&_ss=r. Accessed 12 Nov. 2025. 
• Team, Editorial. “Delta Sleep Inducing Peptide (DSIP): Reviewing the Research.” BioLongevity Labs, 21 Oct. 2025, biolongevitylabs.com/research/dsip-delta-sleep-inducing-peptide/?tw_source=google&tw_adid=&tw_campaign=22124776050&tw_kwdid=&gad_source=1&gad_campaignid=22131035699&gbraid=0AAAAA-VNyo4Uc2QKR49_lCuPUVOX6zg2r&gclid=CjwKCAiA_dDIBhB6EiwAvzc1cGN8P24Fn0433DO34wcbGsIJ_fpmMN_5R3L-PEACRcbgLn_HMTZykhoC4zYQAvD_BwE. 
• Inc., Swolverine. “Melatonin for the Treatment of Primary Sleep Disorders.” Swolverine, Swolverine, 25 Oct. 2021, swolverine.com/blogs/clinical-studies/melatonin-for-the-treatment-of-primary-sleep-disorders. 
• Reconnecting Neurons. Empowering for Life. Dosage Recommendation Stroke TBI, cerebrolysin.com/wp-content/uploads/2022/06/CERE_Dosage-recommendation_CEREINT122018-19.pdf. Accessed 12 Nov. 2025.